OxThera AB

Allena

This biopharmaceutical company develops oral enzyme therapeutics for patients with rare and severe metabolic and kidney disorders, such as hyperoxaluria.

Calliditas therapeutics

This biopharmaceutical company develops and commercialises medicines for patients with rare renal and hepatic diseases.

Pathalys Pharma

This biopharmaceutical company develops treatments for secondary hyperparathyroidism in patients with end-stage kidney disease undergoing dialysis.

River Renal

This clinical-stage biotechnology company develops novel pharmaceutical therapies targeting orphan renal diseases for patients with unmet medical needs.

Omthera Pharmaceuticals

This biopharmaceutical company develops omega-3 fatty acid therapies to treat patients with dyslipidemia and high triglyceride levels.

BEO Therapeutics

This company develops oral microbiome therapies to treat patients with gouty arthritis and chronic kidney disease by reducing metabolic waste products.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

Oncorena Holding AB

This pharmaceutical company develops a synthetic orellanine therapy for patients with metastatic renal cancer.